CLAIMS:

- 1. A preparative method for isolating RNA comprising an oligo- or polynucleptide from a sample, which method comprises:
- (a) treating the sample with a reactant capable of covalently modifying the 2'-OH position of the ribose rings of the RNA under conditions so that a proportion of the 2'-OH positions of the ribose rings bear a substituent; and (b) preparing isolated RNA therefrom by separating
- (b) preparing isolated RNA therefrom by separating material containing the substituent from the sample on the basis of a property of the substituent.
- 2. A method according to etaim 1, wherein step (a) is carried out in a reaction medium which comprises an organic solvent.
- 3. A method according to dlaim 2, wherein the organic solvent comprises an organic base.
- 4. A method according to claim 2 or claim 3, wherein the reactant comprises an acid anhydride, an acid chloride, a carboxylic acid or an N-acylimidazole.
- 5. A method according to claim 4, wherein the reaction medium further comprises an acylation catalyst.
- 6. A method according to any one of claims 2 to 5, wherein the reaction medium further comprises water.

- 7. A method according to any one of the preceding claims, wherein the RNA comprises mRNA, rRNA or viral RNA.
- 8. A method according to any one of the preceding claims, wherein the sample comprises a sample from a biological source.
- 9. A method according to any one of the preceding claims, wherein the sample includes DNA.
- 10. A method according to any one of the preceding claims, wherein the substituent comprises a solid phase.
- 11. A method according to claim 10, wherein the solid phase comprises benzoyl chloride polymer bound (BCPB) beads, silica particles or particles of a glass.
- 12. A method according to claim 10 or claim 11, wherein the solid phase is modified to introduce a reactive group which reactive group is capable of reacting with RNA to capture the RNA on the solid phase.
- 13. A method according to claim 12, wherein the reactive group is introduced by modifying the solid phase with a bi-functional acid halide.
- 14. A method according to any one of claims 1-9, wherein the substituent comprises a hydrophobia substituent.
- 15. A method according to claim 14, wherein the hydrophobic substituent comprises a substituent, OR,

wherein R\ comprises C_1-C_{36} alkyl; C_1-C_{36} alkenyl; C_1-C_{36} $\downarrow_{1-C_{36}}$ haloalkyl; $C_{1}-C_{36}$ aminoalkyl; alkynyl; alkoxyalkyl λ C₁-C₃₆ alkylthioalkyl; C₁-C₃₆ alkoxyalkoxyalkyl; C_1-C_{36} haloalkoxyalkyl; C_1-C_{36} aminoalkoxyalkyl; C_6-C_{36} aryl; C_6-C_{36} alkyla $\frac{1}{4}$ yl; C_6-C_{36} arylalkyl; C_6-C_{36} arylalkenyl; C_1-C_{36} alkanoyl; $C_1 \downarrow C_{36}$ alkenoyl; $C_1 - C_{36}$ haloalkenoyl; $C_1 - C_{36}$ haloalkanoyl; \setminus C₂-C₃₆ haloformylalkanoyl; $C_1 - C_{36}$ aminoalkanoyl; $\backslash C_1-C_{36}$ azidoalkanoyl; C_1-C_{36} carboxyalkanoyl; C_1-C_{36} carboxy alkenoyl; C_1-C_{36} carboxyalkynoyl; C_1-C_{36} alkoxycarbonyl; C_1-C_{36} alkylaminoarylalkanoyl; C_1-C_{36} alkylsulfonyl; C6-C36 alkenyloxycarbonyl; arylalkanoyl; $C_6-\clip{t}_{36}$ arylalkenoyl; C_6-C_{36} aryloxyalkanoyl; C_6-C_{36} alkylarylalkanoyl; C_6-C_{36} haloarylalkanoyl; C_6-C_{36} $C_1 - C_{36}$ C1-C36 alkylsilanyl; aminoarylalkanoyl; trialkylsilanyl or 212-C28 diarylphosphano; or a substituent R', wherein R' compriises $C_1 + C_{36}$ alkyl; $C_1 - C_{36}$ alkenyl; $C_1 - C_{36}$ alkynyl; C_1-C_{36} /haloakkyl; C_1-C_{36} aminoalkyl; halo; amino; C_1-C_{36} alkylamino; C_6-C_{36} aryl; C_1-C_{36} alkylaryl or C_1-C_{36} arylalkyl.

- 16. A method according to claim 15, wherein the hydrophobic substituent comprises a C_4 to C_7 carbon chain or ring.
- 17. A method according to claim 16, wherein the reactant comprises butyric anhydride pentanoic anhydride, hexanoic anhydride or benzoic anhydride.
- 18. A method according to claim 16 or claim 17, wherein the proportion of 2'-OH positions bearing the substituent is at least 10%.

- 19. A method according to claim 15, wherein the hydrophobic substituent comprises a C_8 - C_{12} carbon chain or ring.
- 20. A method according to claim 19, wherein the proportion of 2'-OH positions bearing the substituent is in the range 1 to 10%.
- 21. A method according to claim 15, wherein the hydrophobic substituent comprises a C_{12} - C_{36} carbon chain or ring.
- 22. A method according to claim 21, wherein the proportion of 2'-OH positions bearing the substituent is up to 1%
- 23. A method according to any one of claims 14 to 22, wherein step (b) comprises contacting the treated sample from step (a) with a hydrophobic solid phase so as to bind the material containing the hydrophobic substituent and optionally washing the material bound to the solid phase.
- 24. A method according to claim 23, wherein the hydrophobic solid phase comprises hydrophobic particles.
- 25. A method according to claim 23 or claim 24, which further comprises a step of eluting the material bound to the hydrophobic solid phase by treating with a detergent, a chaotrope or a solvent, by lowering the salt concentration or by cleaving the substituent from the 2'-OH position of the ribose rings.

- 26. A method according to any one of claims 14 to 25, wherein step (b) comprises treating the treated sample from step (a) with a lyotrophic salt to aggregate the material containing the hydrophobic substituent as an RNA precipitate, and isolating the precipitate.
- 27. A method according to claim 26, wherein the lyotrophic salt comprises ammonium sulphate, an alkali metal chloride, magnesium chloride or calcium chloride.
- 28. A method according to any one of claims 14 to 22, wherein step (b) comprises treating the treated sample with a non-polar solvent to form a hydrophobic liquid phase which contains the material containing the hydrophobic substituent, and isolating the hydrophobic liquid phase.
- 29. A method according to claim 28, wherein the non-polar solvent comprises pentane, cyclohexane, toluene, benzene, light petroleum, xylene or hexane.
- 30. A kit for the preparative isolation of RNA comprising an oligo- or polynucleotide from a sample, which kit comprises:
- (i) a reaction system for modifying the RNA to form a modified oligo- or poly-nucleotide in which a proportion of the 2'-OH positions of the ribose rings bear a substituent; and
- (ii) a separation system for preparing isolated RNA by separating material containing the substituent from the sample on the basis of a property of the substituent.

- 31. A kit according to claim 30, wherein the reaction system comprises:
- (a) an organic solvent; and
- (b) a reactant capable of covalently modifying the 2'-OH position of the ribose rings of the RNA in the presence of the organic solvent.
- 32. A kit according to claim 31, wherein the organic solvent comprises an organic base.
- 33. A kit according to claim 31 or claim 32, wherein reactant comprises an acid anhydride, an acid chloride, a carboxylic acid or an N-acylimidazole.
- 34. A kit according to claim 33, which further comprises an acylation catalyst.
- 35. A kit according to any of claims \$1 to 34, wherein the substituent comprises a solid phase.
- 36. A kit according to claim 35 wherein the solid phase comprises benzoyl chloride polymer bound (BCPB) beads, silica particles or particles of a glass.
- 37. A kit according to any one of claims 31 to 34, wherein the substituent comprises a hydrophobic substituent.
- 38. A kit according to claim 37, wherein the hydrophobic substituent comprises a substituent, OR, wherein R comprises C_1 - C_{36} alkyl; C_1 - C_{36} alkenyl; C_1 - C_{36} alkynyl; C_1 - C_{36}

- 42. A kit according to claim 37, wherein the hydrophobic substituent comprises a C_8 - C_{12} carbon chain or ring.
- 43. A kit according to claim 42, wherein the proportion of 2'-OH positions bearing the substituent is in the range 1 to 10%.
- 44. A kit according to claim 37, wherein the hydrophobic substituent comprises a C_{12} - C_{36} carbon chain or ring.
- 45. A kit according to claim 44, wherein the proportion of 2'-OH positions bearing the substituent is up to 1%
- 46. A kit according to any one of claims 37 to 45, wherein the separation system comprises a hydrophobic solid phase for binding the material containing the substituent.
- 47. A kit according to claim 46, wherein the hydrophobic solid phase comprises hydrophobic particles.
- 48. A kit according to claim 46 or claim 47, wherein the separation system further comprises an elution medium for eluting RNA bound to the hydrophobic solid phase.
- 49. A kit according to any one of claims 37 to 45, wherein the separation system comprises a lyotrophic salt for aggregating the material containing the hydrophobic substituent.
- 50. A kit according to any one of claims 37 to 45, wherein the separation system comprises a non-polar solvent for

 C_1-C_{36} aminoalkyl; C_1-C_{36} alkoxyalkyl; C_1-C_{36} haloalkyl; alkylthioalkyl; C1-C36 alkoxyalkoxyalkyl; C1-C36 haloalkoxyalk γ 1; C_1 - C_{36} aminoalkoxyalk γ 1; C_6 - C_{36} ary1; C_6 - C_{36} alkylaryl; $C_6 \downarrow C_{36}$ arylalkyl; $C_6 - C_{36}$ arylalkenyl; $C_1 - C_{36}$ alkanoyl; C_1-C_{16} alkenoyl; C_1-C_{36} haloalkenoyl; C_1-C_{36} haloalkanoyl; C_2 - C_{36} haloformylalkanoyl; C_1 - C_{36} C_1 - C_{36} aminoalkanoyl; $C_1 \setminus C_{36}$ azidoalkanoyl; $C_1 - C_{36}$ carboxyalkanoyl; C_1-C_{36} carboxyalkanoyl; C_1-C_{36} carboxyalkynoyl; C1-C36 alkylaminoarylalkan**d**yl; C_1-C_{36} alkoxycarbonyl; C1-C36 alkenyloxycarbonyl; $C_1 - C_{36}$ alkylsulfonyl; $C_6 - C_{36}$ arylalkanoyl; C_6-C_{36} arylalkanoyl; C_6-C_{36} aryloxyalkanoyl; C_6-C_{36} alkylarylalkanovl; C_6-C_{36} haloarylalkanovl; C_6-C_{36} aminoarylalkanoyl; C1-C36 alkylsilanyl; C1-C36 trialkylsilanyl or C12-C2 d/ary phosphano; or a substituent R', wherein R' comprises C_1-C_{36} alkyl; C_1-C_{36} alkenyl; C_1-C_{36} alkynyl; C_1-C_{36} haloalky $\frac{1}{4}$; C_1-C_{36} aminoalkyl; halo; amino; C_1-C_{36} alkylamino; C_6-C_3 aryl; C_1-C_{36} alkylaryl or C_1-C_{36} arylalkyl.

- 39. A kit according to daim 8, wherein the hydrophobic substituent comprises a C_4 to C_7 carbon chain or ring.
- 40. A kit according to claim 39, wherein the reactant comprises butyric anhydride, pentanoic anhydride, hexanoic anhydride or benzoic anhydride.
- 41. A kit according to claim 39 or claim 40, wherein the proportion of 2'-OH positions bearing the substituent is at least 10%.

- forming a hydrophobic liquid phase which contains the material containing the hydrophobic substituent.
- 51. A preparative device for isolating RNA comprising an oligo-or polynucleotide from a sample from a subject, which device comprises:
- (i) a means for extracting the sample from the subject;
- (ii) a reaction system for modifying RNA in the sample to form a modified oligo- or poly-nucleotide in which a proportion of the 2'-OH positions of the ribose rings bear a substituent; and
- (iii) a separation system for preparing isolated RNA by separating material containing the substituent from the sample on the basis of a property of the substituent.
- 52. A device according to claim 51, wherein the means for extracting the sample from the subject comprises a syringe needle.
- 53. A device according to claim 51 or claim 52, wherein the substituent comprises a solid phase.
- 54. A device according to claim 53, wherein the solid phase comprises a membrane, a particle, a bead, a filter, a fibre, a gel, a strip, a matrix, a resin, a capillary or the walls of a vessel.
- 55. A device according to any of claims 51-54, wherein the sample comprises biological material.

56. A device according to claim 55 which device further comprises a filter for emoving red and/or white blood cells.

AI